References
- Cooley LA, Lewin SR. HIV-1 cell entry and advances in viral entry inhibitor therapy.j Clin. Viral 26,121–132 (2003).
- Gulick RM. New antiretroviral drugs. Gun. 11/licrobiol Infect. 9,186-193 (2003).
- Reynes J, Rouzier R, Kanouni T, et al SCH C: safety and antiviral effects of a CCR5 receptor antagonist in HIV-1-infected subjects. 9th Corti Retrovir. Opportun. Infect. Seattle, WA, USA (2002).
- McCune JM. The dynamics of CD4+ T-cell depletion in HIV disease. Nature 410(6831), 974–979 (2001).
- Jelde A, Keppler OT, De Clercq E, et al hi vi vo evolution of human immunodeficiency virus type 1 toward increased pathogenicity through CXCR4-mediated killing of uninfected CD4 T cells. J. Viral 77, 5846–5854 (2003).
Websites
- GJ Bridger. New drugs, new targets. AMD070: a new class of HIV entry inhibitors that target CXCR4, a chemokine receptor. 14th Internat. AIDS Can( Barcelona, Spain www.anormed.com/documents/14th_aids_ conference.pdf (Viewed August 2003)
- Anormed products www.anormed.com/products/index.html (Viewed August 2003)